Education
About Us
Working with TipRanks
Follow Us
Assembly Biosciences (ASMB)
NASDAQ:ASMB
ASMB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$10.27 - $19.93
Previous CloseN/A
Volume7.37K
Average Volume (3M)30.02K
Market Cap
$81.79M
Enterprise Value-$5.14M
Total Cash (Recent Filing)$41.47M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.75
Next Earnings
May 08, 2025EPS Estimate
-1.6Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.71
Shares Outstanding7,503,385
10 Day Avg. Volume32,465
30 Day Avg. Volume30,018
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.47
Price to Cash Flow (P/CF)-1.20
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.06
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.12
Enterprise Value/Ebitda0.11
Forecast
1Y Price Target
$31.00Price Target Upside191.90% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Assembly Biosciences News
---
Bulls Say, Bears Say
Bulls Say
Drug DevelopmentABI-5366 was safe and well-tolerated with up to 70 days of exposure with healthy volunteers in Phase 1a.
Financial PerformanceAssembly received $30.1M in cash infusions from Gilead.
InvestmentGilead's latest equity investment (priced at a premium) raises Gilead's ownership of outstanding ASMB voting stock from approximately 19.9% to 29.9%.
Bears Say
Regulatory ApprovalThere is current uncertainty on the efficacy of Assembly's programs including ABI-5366, ABI-4334, and ABI-6250, at a level that could potentially support their advancement towards regulatory approvals.
Research And DevelopmentData readout for ABI-5366, originally expected in the first half of 2025, has been delayed to Fall 2025.
Trial RisksKey risks include failed or equivocal trial results, unforeseen safety or tolerability issues, meaningful delays to expected timelines, and inability to sufficiently fund operations.
---
Ownership Overview
48.32% Insiders
5.93% Mutual Funds
40.42% Other Institutional Investors
1.83% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ASMB FAQ
What was Assembly Biosciences’s price range in the past 12 months?
Assembly Biosciences lowest stock price was $10.27 and its highest was $19.93 in the past 12 months.
What is Assembly Biosciences’s market cap?
Assembly Biosciences’s market cap is $81.79M.
When is Assembly Biosciences’s upcoming earnings report date?
Assembly Biosciences’s upcoming earnings report date is May 08, 2025 which is in 40 days.
How were Assembly Biosciences’s earnings last quarter?
Assembly Biosciences released its earnings results on Mar 20, 2025. The company reported -$1.54 earnings per share for the quarter, beating the consensus estimate of -$1.795 by $0.255.
Is Assembly Biosciences overvalued?
According to Wall Street analysts Assembly Biosciences’s price is currently Undervalued.
Does Assembly Biosciences pay dividends?
Assembly Biosciences does not currently pay dividends.
What is Assembly Biosciences’s EPS estimate?
Assembly Biosciences’s EPS estimate is -1.6.
How many shares outstanding does Assembly Biosciences have?
Assembly Biosciences has 7,503,385 shares outstanding.
What happened to Assembly Biosciences’s price movement after its last earnings report?
Assembly Biosciences reported an EPS of -$1.54 in its last earnings report, beating expectations of -$1.795. Following the earnings report the stock price went up 2.993%.
Which hedge fund is a major shareholder of Assembly Biosciences?
Currently, no hedge funds are holding shares in ASMB
---
Assembly Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$31.00 (191.90% Upside)
$31.00 (191.90% Upside)
Hedge Fund Trend
Decreased
By 890.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $50.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 3.2%
Last 30 Days ▼ 3.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-18.53%
12-Months-Change
Fundamentals
Return on Equity
-107.92%
Trailing 12-Months
Asset Growth
-12.73%
Trailing 12-Months
Company Description
Assembly Biosciences
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
---
ASMB Stock 12 Month Forecast
Average Price Target
$31.00
▲(191.90% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
Gilead Sciences
―
Ionis Pharmaceuticals
―
Neurocrine
―
Enanta Pharmaceuticals
―
Best Analysts Covering ASMB
1 Year
1 Year Success Rate
3/28 ratings generated profit
1 Year Average Return
-42.45%
assigned a buy rating 6 months ago
Copying Salim Syed's trades and holding each position for 1 Year would result in 10.71% of your transactions generating a profit, with an average return of -42.45% per trade.
---